Genomic markers of resistance to first-line (1L) therapy with a CDK4/6 inhibitor (CDKi) and endocrine therapy (ET) in patients (pts) with hormone receptor–positive (HR+) metastatic breast cancer (MBC).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Albert Grinshpun, Yvonne Y. Li, Melissa E. Hughes, Alyssa Patterson, Gregory John Kirkner, Maxwell Roger Lloyd, Sarah Strauss, Anna-Marrie Feeney, Janet Files, Colin MacKichan, Sarah L. Sammons, Lynette M. Sholl, Bruce E. Johnson, Deborah Dillon, Eric P. Winer, Andrew D. Cherniack, Sara M. Tolaney, Nancy U. Lin, Rinath Jeselsohn
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162484092
Cites:
Cited by:
Related to: